NEV-801 CML Chronic Myeloid Leukemia
"During its pre-clinical proof-of-concept studies, NEV-801 showed exciting potential, including curative effects, to treat Chronic Myeloid Leukemia that had become resistant to the gold-standard therapy (imatinib), as well as advanced colon cancer that had become resistant to multiple therapies. No bone-marrow toxicity or gastro-intestinal side effects were observed at the highest administered doses in pre-clinical studies"
Extract of Seattle Biotech Neovia Begins Clinical Trial for Immunotherapy Enhancing Cancer Drug
